Sorafenib prolongs survival of patients with unresectablehepatocellular carcinoma (HCC). It is likely to be used in human immunodeficiency virus (HIV) infected patients. Interactions between sorafenib and highly active antiretroviral therapy (HAART) have not been studied yet. We report a case of serious adverse effects in anHIV-1 patient co-infected with HBV.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
suspected interaction
4
interaction sorafenib
4
sorafenib haart
4
haart hiv-1
4
hiv-1 infected
4
infected patient
4
patient case
4
case report
4
report sorafenib
4
sorafenib prolongs
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!